PharmaShots | Incisive News in 3 Shots

Subscribe Now

Basilea

Basilea Reports the NDA Submission of Ceftobiprole for the Treatment of Severe Bacterial and Fungal Infections

Basilea Reports the NDA Submission of Ceftobiprole for the Treatment of Severe Bacterial and Fungal Infections

August 4, 2023

Basilea Entered into an Asset Purchase and Sub-License Agreement with SillaJen for BAL0891

Basilea Entered into an Asset Purchase and Sub-License Agreement with SillaJen for BAL0891

September 20, 2022

Basilea Reports Results of Ceftobiprole in the P-III (ERADICATE) Study for the Treatment of Staphylococcus Aureus Bacteremia

Basilea Reports Results of Ceftobiprole in the P-III (ERADICATE) Study for the Treatment of Staphylococcus Aureus Bacteremia

June 28, 2022

Basilea and Pfizer Collaborated to Commercialize Cresemba for Invasive Aspergillosis and Mucormycosis

Basilea and Pfizer Collaborated to Commercialize Cresemba for Invasive Aspergillosis and Mucormycosis

June 17, 2022

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us